Biosciences
Our researchers in have a rich legacy of collaboration with government agencies and industry partners that improve health outcomes and well-being around the world. SRI Biosciences projects range from high-impact, early-stage research to drug co-development with pharmaceutical and biotech companies.
-
BioCyc database collection
A comprehensive website for sharing fundamental information about biochemical pathways and genomes with researchers around the world
-
Techneins™ – Non-natural polymers as synthetic affinity reagents and novel therapeutics
SRI Biosciences has developed a molecular discovery platform that enables the synthesis and screening of sequence-defined non-natural polymers, or “Techneins™”, to create potent and selective affinity reagents that can be used as either therapeutics or diagnostic reagents.
-
SynFini™
SRI Biosciences has developed SynFini™, a suite of tools that leverages AI to automate the translation of ideas into testable physical molecules.The SynFini platform helps scientists maximize time spent on what to make, rather than how to make by accelerating chemistry design, developme
-
FOX Three Molecular Guidance System (MGS)™
SRI Biosciences has developed the FOX Three Molecular Guidance System™ platform to deliver any cargo to selected cell types, then internalize into those cells to targeted subcellular locations.
-
Ian Colrain talks about SRI Biosciences
Ian Colrain is the former President of SRI’s Biosciences Division in Menlo Park, CA. Join us to learn how SRI Biosciences partners with organizations worldwide to bring new medicines and devices to market through basic research, pharmaceutical and technology discovery, preclinical development and clinical translation. provides services that span all stages of drug and diagnostics…
-
Mary Lanier talks about SRI Biosciences’ response to the ongoing COVID-19 pandemic
Mary Lanier is a Research Scientist at SRI Biosciences in Menlo Park, CA. Join us to learn how SRI Biosciences is responding to the COVID-19 pandemic—from using existing drug discovery and delivery platforms to innovate vaccines and treatment, to rapid testing capabilities, to developing new vaccines that could protect against future viruses. Learn more about…
-
75 Years of Innovation: Twin Research Registry
The Twin Research Registry is a community registry of identical and fraternal twins to help in research into diseases, traits and behaviors
-
SRI International’s Parijat Bhatnagar receives DARPA award to continue groundbreaking research into engineered immunity
The prestigious award provides additional funds to continue developing cells that can be stimulated via extracorporeal devices to treat viral infections
-
SRI International enters drug discovery and research collaboration with Sanofi
Researchers will leverage SynFini, SRI’s artificial intelligence and automation platform, to accelerate development of small-molecule drug targets
-
Targeted Antigen Loaded Liposomes (TALL™)
SRI scientists exploit the human immune response to target cancer cells and extend the benefits of cancer immunotherapies. SRI’s Targeted Antigen Loaded Liposomes (TALL), a new immunotherapy with the potential to overcome these challenges and extend the benefits of immunotherapy to many more patients.
-
SRI International releases major update to its BioCyc family of websites
SRI International is pleased to announce a major update to the BioCyc family of websites. SRI’s BioCyc solution features a collection of nearly 18,000 Pathway/ Genome Databases (PGDBs) for sequenced bacteria and major eukaryotes and supporting software tools. BioCyc provides a reference on the genomes, metabolic pathways of thousands of sequenced organisms and the regulatory networks of some of the organisms. BioCyc data is obtained by combining computational inferences, import data from other databases, and…
-
SRI International receives IARPA contract for rapid, breath-based disease-detection system
SRI International has been awarded a contract under the Intelligence Advanced Research Projects Activity (IARPA) to evaluate whether a novel, prototype technology has the potential to detect COVID-19 and other infectious diseases through exhaled human breath. The rapid, noninvasive technology is designed to provide widespread disease screening in places such as malls, airports, stadiums, emergency…